doi: 10.1161/CIRCRESAHA.120.315937 3 AdakA.KhanM
Learn about the evolutions in treatment since the FDA approved Rezdiffra as the first MASH-specific therapy, including how GLP-1s like Wegovy show promise in liver health, plus comparative insights and a pipeline outlook
Br J Pharmacol 179(4): 600624
Jun 03, 2024 5 min read 5133 views Wondering what is glutathione
Clinically, a prominent and unresolved challenge is the lack of sensitive, specific, and easily accessible biomarkers to accurately and non-invasively detect intra-articular ferroptosis activity or GPX4 functional status
34,35 However, the controversy surrounding the possible benefits of GIPR agonism stems from two main observations: its impaired insulinotropic effects, 36,37 and the prevention of weight gain by suppression of endogenous GIP-induced adipogenesis, 38,39 However, these seemingly discouraging observations have been questioned by the finding of the central anorexic effects of GIP, 4042 and benefits of the GLP-1R/GIPR dual agonist LY3298176 (tirzepatide) in diabetic and overweight individuals